Razis E, Arlin Z A, Ahmed T, Feldman E J, Puccio C, Cook P, Chun H G, Helson L, Mittelman A
Division of Neoplastic Diseases, New York Medical College, Valhalla 10595.
Acta Haematol. 1994;91(4):171-4. doi: 10.1159/000204328.
Tumor lysis syndrome (TLS) is a complication associated with electrolyte abnormalities that is observed in patients with acute leukemia who are receiving intense doses of chemotherapy. Forty-one patients with acute leukemia were treated with high-dose combination chemotherapy and were evaluated for TLS. A grading system developed for the evaluation of these patients was applied. Grade I tumor lysis was observed in 22 patients, grade II TLS in 2 patients and grade III in 1 patient. All patients were treated with intravenous fluids, mannitol, allopurinol and in some patients, aluminum-based antacids. Treatment for TLS prior to intensive chemotherapy reduced morbidity and mortality associated with high-dose chemotherapy for acute leukemias.
肿瘤溶解综合征(TLS)是一种与电解质异常相关的并发症,见于接受大剂量化疗的急性白血病患者。41例急性白血病患者接受了大剂量联合化疗,并对其进行了肿瘤溶解综合征评估。应用了为评估这些患者而制定的分级系统。22例患者观察到Ⅰ级肿瘤溶解,2例为Ⅱ级肿瘤溶解综合征,1例为Ⅲ级。所有患者均接受了静脉补液、甘露醇、别嘌醇治疗,部分患者还接受了铝基抗酸剂治疗。在强化化疗前对肿瘤溶解综合征进行治疗可降低与急性白血病大剂量化疗相关的发病率和死亡率。